Viral Vaccines
OwnerBrian Lichty, Carolina Ilkow +4inventors
InventorsBrian Lichty, Carolina Ilkow, Zhou Xing, Myrna Dolovich, Fiona Smaill, Kyle Stephenson
Life of this patent
Estimating the term…
Abstract
A trivalent transgene that encodes a viral surface glycoprotein component, a viral nucleoprotein component and a viral RNA polymerase component is provided. Vaccines incorporating the trivalent transgene are also provided, along with methods of vaccinating mammals to protect against viral infection.
Claims35
A trivalent transgene for use in a viral vaccine, wherein said trivalent transgene encodes:
- i) a viral surface glycoprotein component comprising a signal peptide and a viral surface glycoprotein coupled to a transmembrane domain that functions to anchor the surface glycoprotein for extracellular expression;
- ii) a viral nucleoprotein component that complexes or associates with viral RNA;
- and
- iii) a viral RNA polymerase component.
A replication-incompetent E1/E3-deleted adenoviral vector.
A kit comprising an adenovirally-vectored vaccine in combination with a nebulizer.
A method of vaccinating a mammal against infection by a virus comprising administering to the mammal an adenovirally-vectored vaccine with a nebulizer.
A trivalent transgene for use in a vaccine effective against a positive single-stranded RNA virus, wherein said trivalent transgene encodes:
- i) a first viral surface glycoprotein component comprising a signal peptide and a viral surface glycoprotein coupled to a transmembrane domain that targets an extracellular vesicle and functions to anchor the surface glycoprotein to the vesicle for extracellular expression;
- and
- ii) a second protein comprising a viral nucleoprotein component that complexes or associates with viral RNA and a viral RNA polymerase component,
- wherein the first glycoprotein component and the second protein are linked with a self-cleaving peptide.
Dependencies are inferred from the claim text.